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Introduction
Cardiovascular disease (CVD) represents a leading cause of death globally. 1 Most often men and women above 55 and 65 years of age, respectively, are affected, but fatty streaks start developing at a very young age and the progression of atherosclerosis is positively associated with plasma low-density lipoprotein cholesterol (LDL-c) exposure. [2] [3] [4] This progression is accelerated in individuals with familial hypercholesterolemia (FH), a genetic disorder characterized by elevated LDL-c levels and premature CVD. Mutations in LDLR, APOB, and PCSK9 have been shown to cause FH. The prevalence of FH is estimated to be 1 per 200 to 250 individuals but this lipid disorder is severely underdiagnosed and undertreated. 2, 3 In children with genetically confirmed FH, undertreatment is common as well. 5, 6 Carriers of FH mutations suffer from increased cardiovascular risk, related to a lifelong exposure to increased LDL-c levels. 7 In adults, and to a lesser extent in children, identification of FH affected individuals is difficult because of the overlap of LDL-c levels in both FH and non-FH individuals. 8, 9 In this context, genetic testing can help in the clinical diagnosis of FH and in the screening of affected family members, known as cascade screening. 10, 11 Childhood is the best period to discriminate between mutation-positive and mutation-negative hypercholesterolemia on the basis of plasma LDL-c levels only. 9 Children with LDL-c levels twice .190 mg/dL should be considered as having FH, whereas 2 consecutive LDL-c levels .160 mg/ dL in combination with a family history of hypercholesterolemia or premature CVD are highly suggestive of FH. Finally, children of affected parent(s) with an LDL-c .130 mg/dL are likely to have inherited the mutation. 2 Initiation of statin treatment early in life (around 8 years) is an accepted strategy in clinical practice, 2,12,13 which makes early identification of children with FH clinically relevant.
14 To date's reference ranges are, however, based on old or small-case studies. [15] [16] [17] [18] [19] [20] [21] To provide such reference ranges, we used data of Lifelines, a prospective population-based cohort study, which was initiated in 2006. 22, 23 Using the same cohort, we recently reported that lipid levels in adults are strongly age-and gender-dependent, whereas the data of participants below the age of 18 years were not yet released. 24 For the present study, we have generated age-and gender-based reference values for lipid levels in children, aged 8 till 18 years. These data can help the identification of children at increased risk of atherosclerosis such as children with FH and assist cascade screening in families. 2 
Methods

Study population
The study protocol was approved by the Medical Ethical Committee of the University Medical Center Groningen in the Netherlands, and all participants provided written informed consent. The rationale and design of Lifelines have been described previously. 22, 23 In short, Lifelines is an ongoing prospective population-based cohort study.
Between 2006 and 2013 inhabitants from the 3 northern provinces of the Netherlands (Groningen, Friesland, and Drenthe) between 25 and 50 years of age were approached by their general practitioner to participate. On a positive response, relatives (first-degree family members, including children [$6 months], partner, and parents-in-law) were also invited. Individuals could also participate through self-registration. Of the 167,729 almost exclusively Caucasian participants, 14,801 are children. This multiplegeneration design offers the unique opportunity to study the origins of multifactorial diseases. In total, 85,000 (51%) participants are part of a 2-generation family and 20,000 (12%) of a 3-generation family.
For the present study, we provide cross-sectional population distributions of plasma lipid levels of children screened at the baseline visit. Of the total 14,801 children, 6730 were excluded because of (1) 
Questionnaires, physical examination, and biomaterial collection
The parents of the children received questionnaires specifically suited for the child's age. The questionnaires covered topics on lifestyle, health, nutrition, and development. A physical examination was performed including anthropometry, blood pressure measurement (10 measurements during 10 minutes using Dinamap registration), and pulmonary function tests. Fasting blood samples were drawn after an overnight fast. Fresh samples were transferred to the central laboratory of University Medical Center Groningen for routine clinical chemistry.
Cholesterol measurements
Total cholesterol, LDL-c, high-density lipoprotein cholesterol (HDL-c), and triglycerides were directly measured and were standardized against appropriate controls as described. 24 LDL-c levels were also calculated using the Friedewald formula, 25 but only when triglyceride levels did not exceed 400 mg/dL.
Statistics
Baseline characteristics that follow a normal distribution were reported as mean and standard deviation. Baseline characteristics with a skewed distribution were reported as median and interquartile range.
Smoothed reference curves were generated using Generalized Additive Models for Location, Scale and Shape. 26 Let Y(t) be an outcome variable at age t. We used the Box-Cox-t power transformation with parameters m(t), s(t), and v(t) to transform Y(t) to Z(t) with the following formula 27 : The transformed variable Z(t) then follows a student t-distribution with t(t) degrees of freedom. The relations between the age t and all 4 parameters were modeled with P-splines functions.
To compare our results to previously reported age-and gender-based percentiles, we also calculated age-and gender-based specific percentiles with corresponding age groups. All analyses were performed stratified by sex and carried out using IBM SPSS Statistics, version 22.0 (Armonk, NY: IBM Corp.) or the statistical software R (version 3.2.2).
Results
Study population
As clarified in the methods section, a total of 8071 children were included in our study. Demographic and clinical characteristics of the study population are shown in Table 1 . Mean age was, for both boys and girls, 12 years. Furthermore, Table 1 shows that boys and girls have on average similar lipid profiles, blood pressure, and glucose levels. Supplementary Table 1 shows the number of included children per year of age.
The associations between age and fasting lipid parameters are depicted in Figure 1 In girls, LDL-c levels appeared to be slightly higher compared with boys. As in the boys, a drop in LDL-c was noted starting at 10 years of age, with the lowest values around 14 years of age, thus a little earlier than in boys. The increase in LDL-c at later ages (15.0-17.9) was more pronounced in girls than boys. This is clearly illustrated at 17 years of age, when LDL-c is substantially higher in girls compared with boys for both median (95 mg/dL vs 82 mg/dL) and the 95 th percentile (144 mg/dL vs 126 mg/dL).
In clinical practice, LDL-c levels are often calculated using the Friedewald formula (f-LDL-c). 25 Supplementary Figure 1 Supplementary Figure 1 indicates that the population distribution of f-LDL-c is slightly lower in both boys and girls. Overall, f-LDL-c was approximately 6 mg/dL lower as compared with direct measurement of LDL-c. Clearly, with increasing triglyceride levels, the discrepancy between direct measurement and f-LDL-c increases.
Age, gender, and HDL-c levels At 8 years of age, HDL-c levels are very similar in boys and girls; however, our cross-sectional data show markedly different HDL-c dynamics between genders with aging. HDL-c increases in boys aged 8.0 to 10.9 years followed by a strong decrease between ages 11.0 and 14.9 years, and a subsequent stabilization. In girls, by contrast, HDL-c is generally slowly decreasing with age.
Age, gender, and triglyceride levels all percentiles studied. At the age of 18 years, median triglycerides were 47% higher in boys and 46% higher in girls compared with the boys and girls aged 8 years.
Extremes
In our study population, a considerable number of children presented with severe hypercholesterolemia: 375 (4.6%) children presented with LDL-c levels .130 mg/dL. Eighty (1.0%) children showed LDL-c .160 mg/dL, which is a strong indicator of having FH. Eighteen children (0.22%) presented with LDL-c levels .190 mg/dL and could be considered as having FH (Table 2) .
Discussion
This study provides tables with age-and gender-based percentiles for lipid and lipoprotein levels in children and adolescents, which can aid clinicians in the diagnosis of dyslipidemia, and in their decisions if additional diagnostic evaluations are indicated. This will allow to distinguish severe dyslipidemia, where pharmacological therapy might be indicated, from lipid abnormalities in need of lifestyle advice. We believe that the presented reference ranges are a prerequisite for effective screening and identification of children and adolescents with FH. In our study population (children and adolescents of Caucasian descent), we identified a prevalence of 1:450 for FH (LDL-C . 190 mg/dL).
Importance of lipid reference values in clinical practice
Several studies have shown that young children with increased total cholesterol levels, for example above the 90 th percentile, will maintain their percentile ranking over time. 29, 30 This is why timely identification and treatment of children and adolescents with severely elevated cholesterol levels, can be an important step in reducing cardiovascular events. The recommended diet of children with FH should include less consumption of total fat (,30% of calories), saturated fat (,7% of calories), and less than 200 mg of cholesterol/d. Furthermore, the consumption of heart-healthy foods such as fruit, vegetables, and whole grain should be encouraged. 2 Besides diet intervention, cost-effective interventions using low-cost generic statins combined with cholesterol absorption inhibitors are fundamental to FH management. 31 Current guidelines advocate initiating statin treatment in children with FH from the age of 8 years onward. 2, 13 Although long-term data on safety and cardiovascular outcomes for statin treated children are limited, follow-up studies showed normalization of progression of carotid intima-media thickness in statin-treated FH children. 31, 32 Importantly, side-effects have been reported to be rare. 33, 34 Screening for FH is a worldwide challenge. The most commonly used diagnostic criteria for FH (ie, Dutch Lipid Clinic Network and Simon Broome criteria) are however not applicable to children. Currently, 2 times plasma LDL-c levels .190 mg/dL is used as diagnostic criterion, whereas a threshold of 130 mg/dL is used in case of affected family members.
2 Universal pediatric screening of FH (phenotypebased screening) could be effectively incorporated in infant health checkups such as immunization programs. 35 This has been proven to be a highly effective approach, especially if reverse cascade screening to identify affected family members is integrated (genotype-based screening). 9, [36] [37] [38] Age-specific diagnostic LDL-c cutoff criteria for diagnosis of relatives with FH have been published previously. 39 In line with other cross-sectional studies, we show that lipid distributions change with age. 17, 18, 40, 41 When studying adolescents around 11-16 year of age with a pronounced fall in cholesterol levels (see Fig. 1 ), the use of a fixed LDL-c level for a diagnosis of FH can easily result in a misdiagnosis. In case of a clinical suspicion of FH because of, for example, familial presence of hypercholesterolemia or premature CVD, genetic testing can also provide a better tool for diagnosis. Finally, using age-and gender-specific LDL-c cutoff values can also help to identify subjects with FH as we recently showed in young premenopausal women. 42 Comparison with the LRC prevalence study
The LRC Prevalence study, conducted in the United States in 1970s, 40 has provided clinicians and researchers with cross-sectional lipid reference values. 43 Because of differences in lifestyle, cholesterol analysis methods, time of inclusion (w30 year difference), and ethnicity, dissimilarities in the distribution of lipid parameters were anticipated. After matching age groups, we compared the age-and gender-based percentiles from LRC Prevalence study with the Lifelines study (Fig. 2) . LDL-c levels were lower in boys (w8 mg/dL) of the Lifelines cohort during adolescence while this discrepancy was not observed in girls. HDL-c levels were higher in both boys and girls in Lifelines compared with the LRC study, whereas triglycerides were slightly lower. The US National Health and Nutrition Examination Surveys previously showed an initial decline of total cholesterol levels in children and young adults (aged 4-19 years) between 1966 and 1970 and 1988 and 1994 . 15 The detrimental increase in overweight and obesity in children over the past decades, 44 which is associated with dyslipidemia, 28 may have reversed the initial lowering of LDL-c levels observed at that time.
Frequency of pediatric hypercholesterolemia
In our study population, 4.6% of the children presented with LDL-c levels .130 mg/dL. In the United States 19, 21 and Germany, 18 higher percentages were reported, 7.0% and 6.1%, respectively (Table 2 ). It is possible that the lower frequency of hypercholesterolemia in our cohort is related to the use of lipid-lowering drugs, but we cannot verify this as Lifelines pediatrics questionnaires do not cover medication use. By contrast, in a pediatric Brazilian cohort (age 12-17 year), 45 the prevalence of LDL-c .190 mg/dL was lower compared with Lifelines, but this could also be a consequence of declining LDL-c levels in adolescence. It may be noted that statements about frequencies of FH in our population are hampered by 1 time point measurements, instead of recommended repeated measurements.
Strengths and limitations
The strengths of our study are the large number of children included and that the measurement of lipid levels was performed on fresh samples in a single central laboratory. We cannot ensure that our study population is representative of the Dutch pediatric population. The adult Lifelines study cohort has, however, been described to be slightly healthier compared with the larger Dutch population, 22 and it is thus likely that our pediatric cohort population is also healthier. Another limitation is that almost all Lifelines participants are of Caucasian descent, and therefore, our reference ranges may be not applicable to other ethnicities. We could not asses the relationship between pubertal stage and lipid levels as the Tanner stages of pubertal development have not been evaluated in the Lifelines cohort.
Conclusions
Our study provides contemporary age-and gender-based reference values for plasma lipid and lipoprotein levels in children and adolescents. We expect that these lipid and lipoprotein values, translated into age-and gender-specific percentiles, can serve clinicians as an effective and reliable instrument to help identifying children and adolescents with dyslipidemia, especially FH.
